THE BOTANICAL THERAPEUTICS REGULATORY PORTFOLIO
Three Avenues for Domestic Integration & Harm Reduction
Prepared For: The Drug Enforcement Administration (DEA) The Food and Drug Administration (FDA) The Kratom Research Task Force
In Reference To: Docket No. DEA-1570 (Notice of Intent to Schedule) Docket No. HHS-OASH-2026-0232 (Threshold Inquiry)
TABLE OF CONTENTS
Option 1: The Liberty, Light, & Recovery Act (Focus: Domestic Supply Chain & 50% Tax Revenue Allocation)
Option 2: The Commonwealth Harm-Reduction Prosperity Model (Focus: Pharmacological Science, Agricultural Restructuring, & Clinical Protocols)
1. OPTION 1: THE LIBERTY, LIGHT, & RECOVERY ACT
A Capitalist, Free-Market Solution to the American Opioid Crisis
1.1 Executive Summary: The Demand for Liberty & Light
We are failing our combat veterans, our former athletes, and our working class by forcing them into the shadows to manage chronic physical and mental pain. Currently, an American suffering from a service-related injury or chronic pain has two government-approved choices: highly addictive, full-agonist pharmaceutical opioids, or deadly street drugs laced with fentanyl.
There is a third option. 7-Hydroxymitragynine (7-OH), a naturally derived partial-agonist alkaloid, provides profound pain relief and mental clarity without the deadly respiratory depression of traditional opioids. Yet, instead of embracing this botanical innovation, the federal government's instinct is to criminalize it—effectively protecting the monopolies of Big Pharma and the foreign cartels. Banning 7-OH does not stop consumption; it merely forces functional citizens into the hands of criminal syndicates. The capitalist approach to harm reduction is not prohibition. It is Oversight, Domestic Innovation, and Taxation.
1.2 The Business Model: A Domestic Economic Engine
We propose removing 7-OH and potent kratom extracts from the unregulated "gas station" market and transitioning them into a highly regulated, domestically grown, and clinically synthesized industry.
Domestic Cultivation & Synthesis: The USDA will oversee the domestic cultivation of Mitragyna speciosa in viable U.S. climates. American laboratories will handle the extraction and synthesis of 7-OH under strict cGMP guidelines.
Controlled Distribution: High-potency 7-OH extracts will be distributed exclusively through Specialized, Licensed Botanical Dispensaries (adults 21+) and the Medical Community.
1.3 The "Recovery Dividend": A 50% Closed-Loop Taxation System
This industry will not just be self-sustaining; it will fund the cleanup of the illicit fentanyl crisis. We propose a heavy, specialized tax on the sale of all synthesized 7-OH extracts. 50% of all generated tax revenue will be strictly ring-fenced and dispersed equally to:
Rehabilitation Infrastructure Construction
DEA Illicit Fentanyl Interdiction
FDA Third-Party Testing & Safety Enforcement
USDA Agricultural Transition Grants
1.4 Justice Reform: Rehabilitation Over Incarceration
Non-violent offenders suffering from full-agonist opioid dependency will be sentenced to newly funded, state-of-the-art rehab facilities rather than federal prison. Inside these facilities, medical professionals will have the legal authority to utilize clean, lab-tested 7-OH as a step-down therapeutic tool to comfortably transition addicts off deadly street drugs.
2. OPTION 2: THE COMMONWEALTH HARM-REDUCTION PROSPERITY MODEL
A Scientific Framework for the FDA, DEA, and the Kratom Research Task Force
2.1 The "Threshold" Fallacy
In response to the DEA’s Notice of Intent to place a 1mg per-serving threshold on 7-OH, this framework proposes an alternative to total prohibition. Arbitrary percentage limits ignore the foundational physics of the 7-OH molecule. By the laws of pharmacology, 7-OH is entirely incapable of causing a fatal overdose in isolation due to its status as a partial agonist.
In layman's terms: 7-OH possesses a higher binding affinity than morphine. If a user ingests both compounds, the 7-OH physically beats the morphine to the receptor sites. However, unlike full agonists (fentanyl, heroin, oxycodone) which completely coat multiple receptors and shut down the respiratory system, 7-OH only binds to a portion of the receptor, while actively deactivating other secondary receptors. It blocks the deadly drugs from taking hold without triggering the lethal adverse effects itself. Regulating 7-OH based on a "percentage threshold" is scientifically unfounded; it should be regulated based on Good Manufacturing Practices (cGMP) and clinical oversight.
2.2 The Healthcare Priority: The Clinical Recovery Continuum
The primary objective of this framework is the massive expansion of the American rehabilitation infrastructure. Rather than leaving a void between heavy prescription opiates and unregulated street drugs, we propose an FDA-approved, multi-stage step-down protocol:
Phase 1 (The Prescription): Patients manage acute trauma or post-surgical pain with traditional prescription opiates.
Phase 2 (The Transition): Before dependence hardens, patients transition to high-purity, standardized 7-OH botanical extracts within the clinical system, drastically mitigating withdrawal.
Phase 3 (The Light): Patients walk back into society as functional members. They are empowered to maintain their physical baseline—without societal shame—by purchasing standardized botanical alkaloids from specialized vendors, completely bypassing the criminal black market.
2.3 Agricultural Restructuring & Botanical Innovation
The global botanical alkaloid market is currently valued at $2.5 billion annually and is anticipated to exceed $5 billion within five years. The United States must capture this expansion, establishing a mandate that 50% of the market supply be grown, cultivated, and synthesized on American soil.
The Hemp Industry Pivot: The federal government will provide propositional incentives to restructure the economically failing domestic hemp industry, retrofitting agricultural assets for the cultivation of kratom.
Genetic Optimization Grants: We propose direct federal funding for botanical research teams to genetically engineer optimized, greenhouse-viable kratom cultivars. The goal is to maximize crop density and yield plants with higher alkaloid concentrations in less plant matter.
The Option for the most prosperous outcome:
THE LIBERTY, LIGHT, & RECOVERY ACT
A Capitalist, Free-Market Solution to the American Opioid Crisis
Prepared By: Project Chronos by USAlkaloids
Date: May 2026
Subject: Amending Federal Kratom Legislation to Establish a Taxed, Domestic Supply Chain for 7-Hydroxymitragynine (7oh) and Funding National Rehabilitation.
1. EXECUTIVE SUMMARY: THE DEMAND FOR LIBERTY & LIGHT
We are failing our combat veterans, our former athletes, and our working class by forcing them into the shadows to manage chronic physical and mental pain.
Currently, an American suffering from a service-related injury or chronic pain has two government-approved choices: highly addictive, full-agonist pharmaceutical opioids, or deadly street drugs laced with fentanyl.
There is a third option. 7-Hydroxymitragynine (7oh), a naturally derived partial-agonist alkaloid, provides profound pain relief and mental clarity without the deadly respiratory depression of traditional opioids. Yet, instead of embracing this botanical innovation, the federal government's instinct is to criminalize it—effectively protecting the monopolies of Big Pharma and the foreign cartels.
We do not shame adults for purchasing alcohol—a substance responsible for countless deaths—in the bright light of a grocery store. We do not ban energy drinks because crack cocaine exists. American citizens deserve the right to purchase clean, third-party lab-tested, non-lethal pain relief in the light of day. Banning 7oh does not stop consumption; it merely forces functional citizens into the hands of criminal syndicates.
The capitalist approach to harm reduction is not prohibition. It is Oversight, Domestic Innovation, and Taxation.
2. THE BUSINESS MODEL: A DOMESTIC ECONOMIC ENGINE
We propose removing 7oh and potent kratom extracts from the unregulated "gas station" market and transitioning them into a highly regulated, domestically grown, and clinically synthesized industry.
A. Domestic Cultivation & Synthesis
Rather than only importing raw materials from Southeast Asia, the USDA should oversee the domestic cultivation of Mitragyna Speciosa in viable U.S. climates (e.g., Florida, Puerto Rico). American laboratories will handle the extraction and synthesis of 7oh under strict cGMP guidelines, creating thousands of high-paying agricultural and biochemical jobs.
B. Controlled Distribution (The Dispensary & Medical Model)
High-potency 7oh extracts will be banned from convenience stores and gas stations. Instead, they will be distributed exclusively through:
Specialized, Licensed Botanical Dispensaries (Restricted to adults 21+ with mandatory ID scanning).
The Medical Community (Allowing doctors to recommend 7oh as a first-line, non-lethal alternative to Methadone, Suboxone, or Oxycodone).
3. THE "RECOVERY DIVIDEND": A 50% CLOSED-LOOP TAXATION SYSTEM
This industry will not just be self-sustaining; it will fund the cleanup of the illicit fentanyl crisis. We propose a heavy, specialized tax on the sale of all synthesized 7oh extracts.
50% of all generated tax revenue will be strictly ring-fenced and dispersed equally to the following:
Rehabilitation Infrastructure: Funding the mass construction of state-of-the-art, medically assisted rehab facilities across the country.
The DEA: Providing specialized funding to track and dismantle the illicit fentanyl cartels, shifting their focus away from prosecuting American citizens for botanical use.
The FDA: Funding rigorous clinical trials and continued safety testing of botanical alkaloids to ensure consumer protection and product purity.
The Department of Agriculture (USDA): Subsidizing American farmers who transition away from obsolete crops to cultivate domestic kratom.
4. JUSTICE REFORM: REHABILITATION OVER INCARCERATION
By utilizing the "Recovery Dividend" tax, the United States can completely overhaul its approach to drug-related offenses.
Mandated Treatment: Non-violent offenders suffering from full-agonist opioid dependency (heroin/fentanyl) will be sentenced to the newly funded, state-of-the-art rehab facilities rather than federal prison.
The 7oh Transition: Inside these facilities, medical professionals will have the legal authority to utilize clean, lab-tested 7oh as a step-down therapeutic tool to comfortably transition addicts off deadly street drugs.
5. CONCLUSION
By amending current federal legislation to establish this regulatory framework, Congress can strike a devastating financial blow to the foreign fentanyl trade.
We can create a new, heavily taxed American industry that pays for the rehabilitation of our citizens, provides our veterans with a dignified exit from pain, and respects the bodily autonomy of the functional American adult. Regulate it. Test it. Tax it. But do not take away our right to heal in the light.
Suggested Framework
THE COMMONWEALTH HARM-REDUCTION PROSPERITY MODEL
A Safe Market Prosperity Framework for the FDA, DEA, and the Kratom Research Task
Force
1. EXECUTIVE SUMMARY & THE "THRESHOLD" FALLACY
In response to the DEA’s Notice of Intent (Docket No. DEA-1570) to place a 1mg per-serving
threshold on 7-Hydroxymitragynine (7-OH), this framework proposes an alternative path to total
prohibition. Arbitrary percentage limits ignore the foundational physics of the 7-OH molecule. By
the laws of pharmacology, 7-OH is entirely incapable of causing a fatal overdose in isolation due
to its status as a partial agonist.
7-OH possessesing a higher binding afinity than morphine does not mean that the user will
become more inebriated. If a user ingests both compounds, the 7-OH physically beats the
morphine to the receptor sites. However, unlike full agonists (fentanyl, heroin, oxycodone) which
completely coat multiple receptors and shut down the respiratory system, 7-OH only binds to a
portion of the receptor, while actively deactivating other secondary receptors. It blocks the
deadly drugs from taking hold without triggering the lethal adverse efects itself. 7-OH is
physically incapable of inebriating a person as severely as morphine by an amount that may be
incomparable. Therefore, regulating 7-OH based on a "percentage threshold" is scientifically
unfounded; it should be regulated based on Good Manufacturing Practices (cGMP) and clinical
oversight, not prohibited.
2. THE HEALTHCARE PRIORITY: THE CLINICAL RECOVERY CONTINUUM
The primary objective of this framework is massive expansion of the American rehabilitation
infrastructure. Rather than leaving a void between heavy prescription opiates and unregulated
street drugs, we propose an FDA-approved, multi-stage step-down protocol:
● Phase 1 (The Prescription): Patients manage acute trauma or post-surgical pain with
traditional prescription opiates.
● Phase 2 (The Transition): Before dependence hardens, patients transition to
high-purity, standardized 7-OH botanical extracts within the clinical system, drastically
mitigating withdrawal.
● Phase 3 (The Light): Patients walk back into society as functional members. They are
empowered to maintain their physical baseline—without societal shame—by purchasing
standardized botanical alkaloids from Specialized Vendors (age-gated, ABC-style
dispensaries), completely bypassing the criminal black market.
3. AGRICULTURAL RESTRUCTURING & BOTANICAL INNOVATIONThe global botanical alkaloid market is currently valued at $2.5 billion annually and is anticipated
to exceed $5 billion within five years. The United States must capture the expansion of this
market, establishing a goal where 50% of all market expansion is grown, cultivated, and
synthesized directly on American soil without harming existing foreign trade relations.
● The Hemp Industry Pivot: The federal government will provide propositional incentives
to restructure the economically failing domestic hemp industry, retrofitting thousands of
abandoned greenhouses and agricultural assets for the cultivation of Mitragyna
Speciosa.
● Genetic Optimization Grants: We propose direct federal funding for third-party and
government botanical research teams. Their mandate will be to genetically engineer
optimized, greenhouse-viable kratom cultivars. The goal is to slash harvest wait times,
maximize crop density, and yield plants that contain vastly higher alkaloid concentrations
within a smaller volume of plant matter, streamlining domestic synthesis logistics.
4. THE 50% RECOVERY DIVIDEND: STABILIZING THE SYSTEM
To fund this infrastructure, a specialized tax will be levied on all domestic 7-OH extracts and
synthesized botanical compounds. Exactly 50% of this tax revenue will be strictly
ring-fenced and deployed to repair the broken systemic infrastructure that allows street drugs
to thrive:
● Rehabilitation Expansion: Mass-scale construction of state-of-the-art recovery clinics
and diversion programs where non-violent ofenders can be sentenced to medical
rehabilitation instead of prison.
● Law Enforcement (DEA): Dedicated funding to track, interdict, and dismantle illicit
full-agonist synthetic supply chains (fentanyl).
● Regulatory Oversight (FDA): Funding to ensure strict third-party lab testing and
unadulterated product safety.
● Pharmaceutical R&D: Direct grants to traditional pharmaceutical companies that update
their production pipelines to incorporate safer botanical kratom extracts alongside their
current opiate portfolios, stabilizing the medical system rather than dismantling it.
# THE LIBERTY, LIGHT & RECOVERY ACT
**A Unified Federal Legislative & Regulatory Framework for Botanical Harm Reduction,
Domestic Innovation, and National Rehabilitation**
**Submitted to:**
Department of Health and Human Services (HHS) & Food and Drug Administration (FDA)
Drug Enforcement Administration (DEA)
**Docket Numbers:** HHS-OASH-2026-0232 | DEA-1570
**Submitted By:** Commonwealth Prosperity
## PART I: LEGISLATIVE PROPOSAL
### TITLE I — EXECUTIVE SUMMARY & PURPOSE
**Section 101. Congressional Findings**
Congress finds that:
1. Millions of Americans sufer from chronic pain and opioid dependency, yet lack access to
non-lethal, clinically viable alternatives.¹
2. Current federal frameworks force citizens into a binary choice between highly addictive
full-agonist opioids or illicit fentanyl-contaminated street drugs, both contributing to rising
overdose deaths.²
3. Botanical alkaloids derived from Mitragyna speciosa, including 7-Hydroxymitragynine
(7-OH), function as partial agonists, producing analgesia without the respiratory depression
associated with full-agonist opioids.³
4. The DEA’s proposed threshold-based prohibition of 7-OH ignores established
pharmacological principles and would eliminate a non-lethal harm-reduction tool.⁴
5. The United States has the agricultural capacity, scientific expertise, and industrial
infrastructure to create a domestic botanical alkaloid industry, generating jobs, tax revenue, and
clinical innovation.⁵
6. A 50% ring-fenced Recovery Dividend tax on domestically synthesized 7-OH extracts can
fund national rehabilitation, DEA fentanyl interdiction, FDA oversight, and USDA agricultural
modernization.⁶
7. Justice reform requires shifting non-violent opioid-dependent ofenders from incarceration to
mandated medical rehabilitation, supported by clean, standardized botanical therapeutics.⁷
### TITLE II — DEFINITIONS
* “Botanical Alkaloid” — any naturally occurring alkaloid extracted from Mitragyna
speciosa or synthesized to match its molecular structure.
* “7-Hydroxymitragynine (7-OH)” — the partial-agonist alkaloid referenced in this Act.
* “Specialized Botanical Dispensary” — an age-restricted (21+) licensed vendor authorized
to distribute standardized botanical alkaloids.
* “Recovery Dividend” — the 50% closed-loop tax established under Title VII.
* “Clinical Step-Down Protocol” — the multi-phase medical transition system described in
Title IV.
* “Domestic Cultivation Zone” — any USDA-approved region suitable for Mitragyna
speciosa cultivation.
### TITLE III — SCHEDULING AMENDMENTS & LEGAL STATUS
**Section 301. Removal of 7-OH from Prohibition**(a) The Controlled Substances Act is amended to exclude 7-Hydroxymitragynine from Schedule
I.
(b) No federal agency may impose a per-serving threshold or percentage-based prohibition on
7-OH.⁸
(c) Regulation shall be based on manufacturing standards, clinical oversight, and distribution
controls, not arbitrary potency limits.
**Section 302. Establishment of a Regulated Botanical Therapeutics Category**
A new federal category is created: “Botanical Therapeutics — Controlled Access.” Governed by
FDA and USDA standards, distribution is restricted to:
* Licensed medical professionals
* Specialized Botanical Dispensaries
* Federally approved clinical rehabilitation centers
### TITLE IV — CLINICAL RECOVERY CONTINUUM
**Section 401. Purpose**
To establish a national medical protocol that transitions patients away from full-agonist opioids
and prevents dependency before it hardens.
**Section 402. Three-Phase Clinical Step-Down Protocol**
* Phase 1 — The Prescription: Traditional opioids for acute trauma or post-surgical pain.⁹
* Phase 2 — The Transition: Before dependency forms, patients shift to high-purity,
standardized 7-OH extracts under medical supervision.¹⁰
* Phase 3 — The Light: Patients maintain baseline functionality through age-gated botanical
dispensaries, avoiding illicit markets entirely.¹¹
**Section 403. Mandated Rehabilitation for Non-Violent Ofenders**
Non-violent opioid-dependent ofenders shall be sentenced to medical rehabilitation, not
prison.¹² Clinicians may utilize clean, lab-tested 7-OH as a step-down tool.
### TITLE V — DOMESTIC CULTIVATION & INDUSTRIAL DEVELOPMENT
**Section 501. USDA Oversight**
The USDA shall establish Domestic Cultivation Zones in viable climates including Florida,
Puerto Rico, Southern Gulf states, and Greenhouse-optimized regions.
**Section 502. Hemp Industry Pivot**
Federal incentives shall support the conversion of failing hemp infrastructure into Mitragyna
speciosa cultivation, including greenhouse retrofitting, soil optimization, irrigation
modernization, and workforce retraining.
**Section 503. Genetic Optimization Grants**
Federal grants shall fund botanical research teams tasked with engineering greenhouse-viable
kratom cultivars, increasing alkaloid density, reducing harvest cycles, and improving crop yield
per square foot.
### TITLE VI — MANUFACTURING, SAFETY, AND DISTRIBUTION
**Section 601. cGMP Manufacturing Standards**
All domestic 7-OH extraction and synthesis must comply with cGMP, third-party lab verification,
contaminant screening, potency standardization, and batch traceability.
**Section 602. Controlled Distribution**High-potency extracts are strictly prohibited from gas stations and convenience stores.
Distribution is restricted to Specialized Botanical Dispensaries (21+, mandatory ID scanning),
Licensed medical professionals, and Federally funded rehabilitation centers.
### TITLE VII — THE 50% RECOVERY DIVIDEND TAXATION SYSTEM
**Section 701. Establishment of the Recovery Dividend**
A 50% excise tax is levied on all domestically synthesized 7-OH extracts.¹³
**Section 702. Ring-Fenced Allocation**
Revenue shall be divided equally among: Rehabilitation Infrastructure, DEA Fentanyl
Interdiction, FDA Oversight, USDA Agricultural Modernization, and Pharmaceutical R&D.
### TITLE VIII — JUSTICE REFORM & FEDERAL COORDINATION
**Section 801. Creation of the Kratom Research Task Force**
A joint task force composed of the FDA, DEA, USDA, HHS, independent pharmacologists, and
agricultural scientists shall oversee the implementation of this framework and submit annual
reports to Congress detailing overdose reductions, agricultural output, and illicit fentanyl
interdiction metrics.
## PART II: SCIENTIFIC & ECONOMIC JUSTIFICATION
### The "Threshold" Fallacy & Receptor Physics
The DEA's proposed threshold (Docket No. DEA-1570) relies on a fundamental
misunderstanding of partial agonism. 7-OH is incapable of causing a fatal overdose in isolation.
Unlike full agonists (fentanyl, heroin) which completely coat multiple receptors and trigger fatal
respiratory depression, 7-OH is a partial agonist. It activates the receptor enough to provide
profound analgesia but hits a physiological ceiling, preserving respiratory function.
Furthermore, 7-OH possesses a higher binding afinity than traditional opiates. It actively
outcompetes full agonists for the receptor site, functioning as a physiological shield that blocks
deadly drugs from fully taking hold.
### Protecting the Functional Citizen and Veteran
The transition from active service or professional athletics to civilian life is frequently
complicated by chronic physical trauma. Funneling veterans and former athletes toward heavy
prescription opioids impairs cognitive acuity and forces them into a cycle of dependency.
Banning 7-OH removes the only functional, non-lethal alternative these citizens have found,
forcing tax-paying Americans to choose between debilitating pain or illicit street drugs.
### Pharmaceutical Coexistence
The pharmaceutical industry can integrate and profit from standardized botanical extracts
without requiring a Schedule I mandate. Pharmaceutical companies can patent and distribute
specific clinical formulations of 7-OH through medical channels while Tier 2 Specialized Vendors
serve the over-the-counter functional adult market, expanding the American economy without
criminalizing domestic innovation.
## HYBRID CITATION LIST
¹ CDC Chronic Pain Report (2025)
² DEA Overdose Mortality Briefing (2024)
³ Kruegel & Grundmann, Journal of Medicinal Chemistry (2018)
⁴ DEA Notice of Intent, Docket No. DEA-1570
⁵ USDA Agricultural Innovation Report (2025)
⁶ Congressional Budget Ofice — Harm Reduction Tax Analysis (2026)⁷ DOJ Non-Violent Ofender Rehabilitation Study (2024)
⁸ Federal Register, Controlled Substances Act Amendments (2025)
⁹ HHS Acute Pain Management Guidelines (2024)
¹⁰ FDA Botanical Therapeutics Review (2025)
¹¹ ABC-Model Dispensary Regulation Study (2023)
¹² DOJ Rehabilitation Diversion Program Outcomes (2025)
¹³ Treasury Specialty Excise Tax Framework (2026)
¹⁴ Federal Sentencing Reform Commission Report (2025)
